Paul O'Callaghan

Paul O'Callaghan is a Researcher at Uppsala University's Department of Medical Cell Biology within the Faculty of Medicine. His work spans multiple disciplines at the intersection of cell biology, neuroscience, and biomedical engineering. Based at the BMC campus in Uppsala, he maintains an active research program with publications spanning from 2008 to the present, demonstrating sustained scholarly productivity.

Dr. O'Callaghan's research interests focus on cellular mechanisms relevant to neurodegenerative diseases, particularly Alzheimer's disease, with emphasis on amyloid-beta pathology, heparan sulfate proteoglycans, and glial cell biology. His recent work has expanded into biomedical engineering applications including bioprinting, microfluidics, and biomaterials for neural applications. His publication record reveals a trajectory from fundamental cell biology toward translational applications, with consistent focus on cellular signaling mechanisms.

O'Callaghan's recent publications (2021-2024) demonstrate a shift toward more engineering-focused approaches to biological problems, including 3D bioprinting, microfluidic cell culture systems, and biomaterial testing. His work maintains strong connections to both fundamental cell biology questions and potential clinical applications, particularly in neurodegenerative disease and cancer research.

He leads his own research group within the Department of Medical Cell Biology, collaborating extensively with colleagues across Uppsala University including Johan Kreuger, Olle Eriksson, and other researchers in related fields. His work appears in high-impact journals across cell biology, neuroscience, and biomaterials disciplines.